Title: Replacement of carboplatin by oxaliplatin may be one solution for patients treated for ovarian carcinoma who are hypersensitive to carboplatin.
Abstract: shows us a way to predict hypersensitivity to carboplatin, a real problem in clinical practice. Despite prophylaxis, some patients develop a hypersensitivity reaction to carboplatin. The risk for a reaction increases with an increased number of cycles. Platin salts are considered to be one of the major drugs for first-line treatment and for platinum-sensitive recurrence of ovarian carcinoma. Although desensitization has been used successfully, 2 some severe cases of reactions have been reported for cisplatin or carboplatin despite desensitization, including anaphylaxis and death. 3 Oxaliplatin is a platin salt which has been compared with cisplatinum in an ovarian cancer first-line therapy in a multicenter phase II/III study. No significant differences were found for the efficacy parameters between the two arms. 4,5 Although some allergic reactions have been reported with oxaliplatin, 6 no cross-reactivity has been found in the literature between oxaliplatin and carboplatin or between oxaliplatin and cisplatin. We report two cases of patients with a platinum-sensitive recurrence of ovarian carcinoma treated with oxaliplatin after a severe allergic reaction to carboplatin. Before the allergic reactions, they had previously received 11 and 13 courses of carboplatin. Allergic reactions appeared at the fifth and fourth cycle of carboplatin for relapsed disease. Subsequently, three and five courses of oxaliplatin were administered under clinical surveillance during a short hospitalization. No hypersensitivity or minor reactions were reported. In both cases, however, the disease continues to respond. Replacement of carboplatin by oxaliplatin under clinical surveillance may be a solution for patients treated for ovarian carcinoma and developing a hypersensitivity to carboplatin.
Publication Year: 2002
Publication Date: 2002-01-01
Language: en
Type: letter
Indexed In: ['pubmed']
Access and Citation
Cited By Count: 11
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot